tailieunhanh - Health and Quality of Life Outcomes BioMed Central Research Open Access Validity and reliability

Health and Quality of Life Outcomes BioMed Central Research Open Access Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials Richard Shikiar*1, Brian W Bresnahan2, Stephen P Stone3, Christine Thompson4, John Koo5 and Dennis A Revicki4 Address: 1Center for Health Outcomes Research, MEDTAP International, Inc., Seattle, WA USA, 2Health Economics, Genentech, Inc., South San Francisco, CA USA, 3Division of Dermatology, Department of Medicine, Southern Illinois University School of Medicine, Springfield IL USA, 4Center for Health Outcomes Research, MEDTAP International, Inc., Bethesda, MD USA and 5Department of Dermatology, University of California – San Francisco, San Francisco, CA, USA Email: Richard. | BioMed Central Health and Quality of Life Outcomes Research Open Access Validity and reliability of patient reported outcomes used in Psoriasis results from two randomized clinical trials Richard Shikiar 1 Brian W Bresnahan2 Stephen P Stone3 Christine Thompson4 John Koo5 and Dennis A Revicki4 Address 1Center for Health Outcomes Research MEDTAP International Inc. Seattle WA USA 2Health Economics Genentech Inc. South San Francisco CA USA 3Division of Dermatology Department of Medicine Southern Illinois University School of Medicine Springfield IL USA 4Center for Health Outcomes Research MEDTAP International Inc. Bethesda MD USA and 5Department of Dermatology University of California - San Francisco San Francisco CA USA Email Richard Shikiar - shikiar@ Brian W Bresnahan - Stephen P Stone - sstone@ Christine Thompson - thompson@ John Koo - Dennis A Revicki - revicki@ Corresponding author Published 08 October 2003 Received 01 July 2003 Accepted 08 October 2003 Health and Quality of Life Outcomes 2003 1 53 r This article is available from http content 1 1 53 2003 Shikiar et al licensee BioMed Central Ltd. This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Background Two Phase III randomized controlled clinical trials were conducted to assess the efficacy safety and tolerability of weekly subcutaneous administration of efalizumab for the treatment of psoriasis. Patient reported measures of psoriasis-related functionality and health-related quality of life and of psoriasis-related symptom assessments were included as part of the trials. Objective To assess the reliability validity and responsiveness of the patient reported outcome measures that were used in the trials - the Dermatology Life Quality Index DLQI the .

TÀI LIỆU LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.